tibia_actu2_def copy

World first: a child’s tibia healed thanks to a 3D bone graft from Novadip technology

  This is a world first in the field of orthopaedic surgery: surgeons at Cliniques universitaires de Saint-Luc repaired the tibia bone of a 5-year-old child using a bone graft implant, a technology developed by the UCLouvain spin-off Novadip Biosciences. The child had congenital nonunion of the tibia, a rare and disabling disease. He was[…]

univercells_bill_gates

Bill Gates invests in Univercells again

    Univercells has just completed a new funding round of around 50 million €. Among its investors, a fund linked to the Bill & Melinda Gates Foundation, which has already helped the Walloon biotech on several occasions. The list of investors includes Adjuvant Global Health Technology Fund, a fund originally linked to the Bill & Melinda Gates[…]

novadip_3M3_platform

Novadip unveiled its 3M³ Platform at BIO Digital 2020

Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Novadip Biosciences, a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it will unveil details of its 3M3 miRNA delivery platform in a recorded presentation at the BIO Digital conference, which is took place[…]

bonehealing

Novadip progresses in bone healing treatment

Great news for Novadip published in L’Echo and Trends Tendances. Novadip Biosciences – biotech active in cell therapy – has recorded very encouraging results for its product candidate intended to repair large non-healing fractures of the lower limbs in adults. The UCLouvain spin-off has developed a revolutionary process for reconstructing bones from stem cells drawn from the patient’s fat.[…]

pdcline_bfmbusiness

PDC*line Pharma on BMF Business

Eric Halioua, President & CEO of PDC*line Pharma, was invited on BMF Business to speak about the new class of immunotherapies active against cancer which his team is developing. Watch the replay here: Contact us to get more information: Source: https://bfmbusiness.bfmtv.com/mediaplayer/video/eric-halioua-pdcline-pharma-pdcline-pharma-developpe-une-nouvelle-classe-d-immunotherapies-actives-contre-les-cancers-0205-1244108.html  

favicon_20200415_Press-Release-COVID19-Vaccine

Univercells announces fast-track development of a COVID-19 vaccine with ReiThera and Leukocare

ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine. Italian ReiThera Srl. (Rome), German LEUKOCARE AG (Munich), and Belgian Univercells S.A. (Brussels), today announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19. The vaccine candidate is expected to enter[…]

univercells_coronavirus_bultot

Univercells in the race for the coronavirus vaccine

With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot. Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 15,000-square-meter[…]

pdcLine-Pharma-dendritic-cell-cancer-vaccine

PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate targeting non-small cell lung cancer

Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]

univercells_press_release

Univercells secures up to €50M investment from KKR platform

BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]

MaSTherCell_250x250

MaSTherCell is acquired by Catalent for $315 Million

GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]

pdc_biotech_finances

PDC*line Pharma’s recent fund raising is described in the latest issue of Biotech Finances

Check the latest issue of Biotech Finances to read an interview of PDC*line Pharma’s President & CEO Eric Halioua describing the recent fund raising completed and the perspectives of the company.   Read the full article: https://www.biotech-finances.com/126504-2/ Contact us to get more information:

blqDNtyA

Our client PDC*line Pharma raises $22.2M in series B financing round

Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]

BioWin_gdv

We gave a lecture about clinical trials funding at “Anchoring Clinical Research in Belgium”

We took part in the event “Anchoring Clinical Research in Belgium” jointly organized by BioWin and flanders.bio in Brussels where we had an interesting debate on funding opportunities for biomedical research and clinical trials development in a sector where Belgium is leading globally. Thank you to Bone Therapeutics, icometrix and Ayming Belgium for sharing the stage.              […]

DSC6577

Imcyse secures total of €35M in Series B financing round and additional grants

Proud to have helped Imcyse to fundraise 35M€ to carry out clinical trials of treatments for type 1 diabetes, multiple sclerosis and other autoimmune diseases. Please read the article in L’Echo: https://www.lecho.be/entreprises/pharma-biotechnologie/imcyse-se-profile-comme-la-future-pepite-wallonne-de-la-biotech/10137301.html Imcyse secures total of €35M in Series B financing round and additional grants

55931038_784249591956524_1994710630489128960_n

Kick-off of the Human Brain Project’s National Hub for Innovation in Belgium: B.R.A.I.N. hub

B.R.A.I.N. hub (Belgian Research And Innovation in Neurosciences), the second European Human Brain Project’s National Hub for Innovation (HBP-NHI-be), was successfully launched in Belgium thanks to the initiative of Abaxys Therapeutics and our startupstudio.be. Press release: https://gallery.mailchimp.com/86270bb6b0c29cba9301c4907/files/d77b9722-7fd0-4679-9ef4-18cd08f24a6f/BRAINhub_kick_off_press_release_HBP_NHI_be_Mar_2019.pdf?mc_cid=27e3a48b74&mc_eid=6d7be67224

PDCline-tetiere-HOME-HDEF-2

PDC*line Pharma enters into a licensing agreement with leading Korean pharmaceutical company LG Chem

New success story for our customer PDC*line Pharma which enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia. PDC*line Pharma enters into licensing agreement with LG Chem to develop PDC*lung cancer vaccine in Asia

News_201612_Logo-BMGF4-270x270

Univercells receives $12 Million grant from the Bill & Melinda Gates Foundation

Our customer Univercells has been awarded a $12 Million grant by the Bill & Melinda Gates Foundation to develop a breakthrough vaccine manufacturing platform. Its aim is to drastically reduce the cost of vaccines whilst increasing their availability and affordability in developing countries. « Humanity’s greatest advances are not in its discoveries, but in how those discoveries[…]

masthercell_orgenesis

Orgenesis acquires MaSTherCell

Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis’ product and will also maintain his CDMO core business activity in[…]